AbbVie Submits Application to FDA for Risankizumab in Ulcera

AbbVie submitted regulatory applications to the FDA and EMA for rizankizumab 1200 mg intravenous induction dose and 180 mg and 360 mg subcutaneous maintenance dose following successful Phase 3 trials INSPIRE and COMMAND.

Related Keywords

, Roopal Thakkar , Drug Administration , News Center , European Medicines Agency , Development In Regulatory Affairs , Regulatory Affairs , Mayo Score , Fda , Ulcerative Colitis , Rizankizumab , Skyrizi , Abbvie ,